Study 1381.2:
Key eligibility criteria for cohorts open for recruitment

Key inclusion criteria: all Part 2 cohorts

- Adult patients
- ECOG PS 0–1
- Measurable disease per RECIST v1.1
- ≥1 tumor lesion amenable to biopsy

Key inclusion criteria: solid tumors

- High TMB (≥10 mutations/Mb) and/or MSI-H and/or DNA dMMR (measured using any validated test)
- Must have received 1 prior anti-PD-(L)1 treatment regimen

Key inclusion criteria: 1st line squamous or non-squamous NSCLC

- Treatment-naïve
- *EGFR* and *ALK* wild-type
- Any PD-L1 expression (patients with high level of PD-L1 expression [≥50% PD-L1] will be limited to a maximum of 10)

Key inclusion criteria: 2nd or 3rd line NSCLC

- Progression on anti-PD-(L)1 treatment after achieving radiologically confirmed benefit (minimum stable disease)
- Minimum duration of benefit of 8 months for non-squamous NSCLC patients who received immunotherapy + chemotherapy in 1st line setting or 6 months for all other patients
- Anti-PD-(L)1-containing treatment must have been the latest treatment regimen prior to enrolling in this trial
- Latest treatment must be within >4 and <12 weeks before their first dose in this trial
- Patients with prior anti-PD-(L)1 monotherapy as 1st line NSCLC treatment must have PD-L1 expression ≥1% at baseline

Key exclusion criteria

- Prior LAG-3 targeted therapy
- Active brain metastases
- Inadequate organ function

Study 1381.2:
Endpoints and assessments in Part 2

Endpoints

Primary

Objective response

Secondary

Duration of response

Disease control

Progression-free survival

Pharmacokinetic parameters

Safety

Assessments

Efficacy

Investigator-assessed (RECIST v1.1 and irRECIST)
Assessed every 2 cycles (in first 6 months) and then every 3 cycles

Safety

Descriptive analysis of AEs per CTCAE v5

Physical examinations

Laboratory evaluations